Deutsche Bank
AVBP icon

Deutsche Bank’s ArriVent BioPharma AVBP Stock Holding History

Deutsche Bank’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13M Sell
37,376
-1,804
-5% -$55.3K ﹤0.01% 2126
2026
Q2 		$1.36M Buy
39,180
+11,201
+40% +$331K ﹤0.01% 2143
2026
Q1 		$645K Buy
27,979
+6,448
+30% +$146K ﹤0.01% 2443
2025
Q4 		$433K Buy
21,531
+1,559
+8% +$32.5K ﹤0.01% 2649
2025
Q3 		$368K Buy
19,972
+2,392
+14% +$47K ﹤0.01% 2709
2025
Q2 		$383K Sell
17,580
-5,603
-24% -$116K ﹤0.01% 2593
2025
Q1 		$429K Sell
23,183
-953
-4% -$23.3K ﹤0.01% 2562
2024
Q4 		$643K Buy
24,136
+8,805
+57% +$253K ﹤0.01% 2489
2024
Q3 		$360K Buy
+15,331
New +$348K ﹤0.01% 2637

Other funds holding AVBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Deutsche Bank's AVBP Position: Q3 2026 in Review

Deutsche Bank reduced its ArriVent BioPharma (AVBP) stake by 4.6% in Q3 2026, selling an estimated $55.3K and leaving 37,376 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2126.

Deutsche Bank first reported a position in AVBP in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.36M in Q2 2026. 43 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Deutsche Bank held 37,376 shares of ArriVent BioPharma worth $1.13M as of Q3 2026.
  • Deutsche Bank sold 1,804 ArriVent BioPharma shares in Q3 2026, an estimated $55.3K.
  • ArriVent BioPharma made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2126 holding.
  • Deutsche Bank first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 9 quarters since.
  • Deutsche Bank's ArriVent BioPharma position peaked at $1.36M in Q2 2026.
  • 43 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.